Home » Stocks » BCAB

BioAtla, Inc. (BCAB)

Stock Price: $47.42 USD -0.32 (-0.67%)
Updated Apr 19, 2021 1:44 PM EDT - Market open
Market Cap 399.66M
Revenue (ttm) 429,000
Net Income (ttm) -35.85M
Shares Out 8.43M
EPS (ttm) -3.19
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $47.42
Previous Close $47.74
Change ($) -0.32
Change (%) -0.67%
Day's Open 48.00
Day's Range 46.22 - 48.08
Day's Volume 72,266
52-Week Range 27.15 - 76.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

SAN DIEGO, Jan. 8, 2021 /PRNewswire/ -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announ...

3 months ago - PRNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can b...

Other stocks mentioned: FL, GME, NTAP, ARVN, COUP, EOSE, GWRE ...
3 months ago - Benzinga

SAN DIEGO, Dec. 18, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...

4 months ago - PRNewsWire

SAN DIEGO, Dec. 15, 2020 /PRNewswire/ -- BioAtla, Inc. (Nasdaq: BCAB), a clinical-stage biopharmaceutical company developing a novel class of highly specific and selective antibody-based therapeutics fo...

4 months ago - PRNewsWire

San Diego, California-based BioAtla was founded to develop conditionally active biologics that 'exploit characteristic pH differences between the tumor microenvironment and healthy tissue.'

4 months ago - TheStreet

BioAtla, a Phase 2 biotech developing antibody therapies for solid tumor cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

5 months ago - NASDAQ

BioAtla, Inc. has filed to go public with an IPO on the New York Stock Exchange (NYSE).

5 months ago - SEC

About BCAB

BioAtla is a clinical-stage biopharmaceutical company developing our novel class of highly specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Our conditionally active biologics, or CABs, capitalize on our proprietary discoveries with respect to tumor biology, enabling us to target known and widely validated tumor antigens that have previously been difficult or impossible to target. Our novel CAB therapeutic candidates exploit characteristic pH differences between the tumor microenvironment and healthy ti... [Read more...]

Industry
Biotechnology
IPO Date
Dec 16, 2020
CEO
Jay M. Short
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
BCAB
Full Company Profile

Financial Performance

In 2020, BioAtla's revenue was $429,000, a decrease of -91.75% compared to the previous year's $5.20 million. Losses were -$35.85 million, 20.3% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for BioAtla stock is "Buy." The 12-month stock price forecast is 76.67, which is an increase of 61.68% from the latest price.

Price Target
$76.67
(61.68% upside)
Analyst Consensus: Buy